Last quarter (Q2 2024), Kintara Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Kintara Therapeutics's net income was $-1.02M. See Kintara Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 22	Jun 21	Jun 20	Jun 19	Jun 18
Total Revenue	-	-	-	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 10.70M	$ 22.67M	$ 38.29M	$ 8.14M	$ 8.40M	$ 11.17M
Operating Income	$ -10.69M	$ -22.67M	$ -38.29M	$ -8.14M	$ -8.40M	$ -11.17M
Net Non Operating Interest Income Expense	-	-	$ 30.00K	$ 75.00K	$ 60.70K	$ 33.24K
Other Income Expense	-	$ -16.72M	$ -16.72M	$ -1.06M	$ 289.57K	$ 3.11K
Pretax Income	$ -3.71M	$ -22.66M	$ -38.30M	$ -9.13M	$ -8.05M	$ -11.14M
Tax Provision	-	$ -196.00K	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -3.89M	$ -25.13M	$ -41.50M	$ -9.14M	$ -8.13M	$ -11.31M
Basic EPS	$ -6.11	$ -0.52	$ -80.00	$ -0.87	$ -3.16	$ -5.42
Diluted EPS	$ -6.11	$ -0.52	$ -80.00	$ -0.87	$ -3.16	$ -5.42
Basic Average Shares	$ 9.38M	$ 48.70M	$ 517.72K	$ 10.44M	$ 2.57M	$ 2.09M
Diluted Average Shares	$ 9.38M	$ 48.70M	$ 517.72K	$ 10.44M	$ 2.57M	$ 2.09M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 10.70M	$ 22.67M	$ 38.29M	$ 8.14M	$ 8.40M	$ 11.17M
Net Income From Continuing And Discontinued Operation	$ -10.70M	$ -22.66M	$ -38.30M	$ -9.13M	$ -8.05M	$ -11.14M
Normalized Income	$ -3.95M	-	-	$ -8.07M	$ -8.34M	$ -11.14M
Interest Expense	-	-	-	-	-	-
EBIT	$ -10.70M	$ -22.66M	$ -38.33M	$ -8.14M	$ -8.40M	$ -11.17M
EBITDA	$ -8.49M	$ -22.60M	$ -38.20M	$ -8.13M	$ -8.38M	$ -11.15M

Currency in USD

Kintara Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing